Treats the Full Spectrum of Bipolar I Episodes

Depressive, Acute Manic and Mixed1,4-6

VRAYLAR bipolar I depression and mania gauge icon.

Treats the full spectrum of bipolar I episodes

No matter the bipolar I episode (depressive, acute manic or mixed), VRAYLAR is approved to treat it1


Change in MADRS total score in bipolar I depression studies1, 4-6

Study 7 (N=431)1,2,4

Graph showing change in MADRS total score in VRAYLAR vs placebo for bipolar I depression in study 7.

Study 8 (N=474)1,2,5

Graph showing change in MADRS total score in VRAYLAR vs placebo for bipolar I depression in study 8.

Study 9 (N=478)1,2,6

Graph showing change in MADRS total score in VRAYLAR vs placebo for bipolar I depression in study 9.

It is unknown if the statistically significant differences observed at time points earlier than Week 6 represent clinically relevant treatment effects.

Two 6-week and one 8-week randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of VRAYLAR in adult patients (18-65 years old) who met DSM-IV-TR and DSM-5 criteria for depressive episodes associated with bipolar I disorder. The primary statistical analyses were conducted using an MMRM approach. In each study, the primary endpoint was the LS mean change from baseline in MADRS total score at the end of Week 6.1,4-6

VRAYLAR demonstrated efficacy in bipolar I depression, with no more than 2.8% of VRAYLAR patients experiencing
treatment-emergent mania (vs 3.5% in placebo)2*

*Patients with nonmissing baseline and ≥1 postbaseline parameter assessment during the double-blind treatment period—Study 7: VRAYLAR 1.5 mg/day (n=4/145) and VRAYLAR 3 mg/day (n=4/145) compared to placebo (n=5/142); Study 8: VRAYLAR 1.5 mg/day (n=1/153) and VRAYLAR 3 mg/day (n=0/164) compared to placebo (n=2/157); Study 9: VRAYLAR 1.5 mg/day (n=2/162) and VRAYLAR 3 mg/day (n=0/154) compared to placebo (n=2/158).2

DSM=Diagnostic and Statistical Manual of Mental Disorders; LS=least squares; MADRS=Montgomery-Asberg Depression Rating Scale; MMRM=mixed-effects model for repeated measures; TR=text revision.


Post-hoc item analysis of pooled data from VRAYLAR pivotal bipolar I depression studies7

Observed reduction in all individual MADRS item scores at Week 67

MADRS Items (Scored 0-6)

Graph showing post-hoc item analysis in MADRS Items at week 6 for VRAYLAR vs placebo for bipolar I depression.

These analyses were not prespecified endpoints and were not adjusted for multiplicity. Therefore, treatment differences cannot be regarded as statistically significant.

VRAYLAR was approved based on the primary endpoint, mean change in MADRS total score from baseline at Week 6.1

A post-hoc analysis of data pooled from 3 randomized, placebo-controlled, double-blind studies of adult patients with bipolar I disorder. Patients in the ITT population (N=1383) were treated with either placebo (n=460) or VRAYLAR (n=923). VRAYLAR doses 1.5–3 mg/day were pooled for analysis. Mean change from baseline at 6 weeks on individual MADRS items was analyzed using an MMRM approach.7

ITT= intent-to-treat


Change in functional outcomes

Additional efficacy endpoint in one pivotal bipolar I depression trial: Change in Functioning Assessment Short Test (FAST) total score at Week 82

Graph showing change in functional outcomes in VRAYLAR vs placebo at week 8.

These analyses were not prespecified endpoints and were not adjusted for multiplicity. Therefore, treatment differences cannot be regarded as statistically significant.

VRAYLAR was approved based on the primary endpoint, mean change in MADRS total score from baseline at Week 6.1

This 8-week, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of VRAYLAR in adult patients (18-65 years old) who met DSM-IV-TR criteria for depressive episodes associated with bipolar I disorder. The primary statistical analysis was conducted using an MMRM approach. The primary endpoint was the LS mean change from baseline in MADRS total score at the end of Week 6.1,2

SD=standard deviation; SE=standard error.

The FAST evaluates functional impairment8

The FAST is a clinician-rated scale designed to assess functional impairments in patients with bipolar I disorder. It consists of 24 items divided among 6 areas of functioning:

1 icon.

Autonomy

Capacity to do things alone and make their own decisions

2 icon.

Occupational functioning

Capacity to perform and succeed at work

3 icon.

Cognitive functioning

Capacity to concentrate, learn, and problem-solve

4 icon.

Financial issues

Capacity to manage and spend money responsibly

5 icon.

Interpersonal relationships

Capacity to maintain relationships and socialize

6 icon.

Leisure time

Capacity to pursue hobbies and other activities of leisure

Items are rated using a 4-point scale:

0=no difficulty; 1=mild difficulty; 2=moderate difficulty; 3=severe difficulty. The total score is the sum of all 24 items. The higher the score, the more serious the difficulties are.